Vaš brskalnik ne omogoča JavaScript!
JavaScript je nujen za pravilno delovanje teh spletnih strani. Omogočite JavaScript ali pa uporabite sodobnejši brskalnik.
Nacionalni portal odprte znanosti
Odprta znanost
DiKUL
slv
|
eng
Iskanje
Brskanje
Novo v RUL
Kaj je RUL
V številkah
Pomoč
Prijava
Intracellular hydrolysis of small-molecule O-linked N-acetylglucosamine transferase inhibitors differs among cells and is not required for its inhibition
ID
Loi, Elena Maria
(
Avtor
),
ID
Weiss, Matjaž
(
Avtor
),
ID
Pajk, Stane
(
Avtor
),
ID
Gobec, Martina
(
Avtor
),
ID
Tomašič, Tihomir
(
Avtor
),
ID
Pieters, Roland J.
(
Avtor
),
ID
Anderluh, Marko
(
Avtor
)
PDF - Predstavitvena datoteka,
prenos
(1,90 MB)
MD5: F9FAB238294F772015A8EC75E1291F30
URL - Izvorni URL, za dostop obiščite
https://www.mdpi.com/1420-3049/25/15/3381
Galerija slik
Izvleček
O-GlcNAcylation is an essential post-translational modification that occurs on nuclear and cytoplasmic proteins, regulating their function in response to cellular stress and altered nutrient availability. O-GlcNAc transferase (OGT) is the enzyme that catalyzes this reaction and represents a potential therapeutic target, whose biological role is still not fully understood. To support this research field, a series of cell-permeable, low-nanomolar OGT inhibitors were recently reported. In this study, we resynthesized the most potent OGT inhibitor of the library, OSMI-4, and we used it to investigate OGT inhibition in different human cell lines. The compound features an ethyl ester moiety that is supposed to be cleaved by carboxylesterases to generate its active metabolite. Our LC-HRMS analysis of the cell lysates shows that this is not always the case and that, even in the cell lines where hydrolysis does not occur, OGT activity is inhibited.
Jezik:
Angleški jezik
Ključne besede:
ester hydrolysis
,
inhibitor
,
O-GlcNAc transferase
,
OGT inhibitor
Vrsta gradiva:
Članek v reviji
Tipologija:
1.01 - Izvirni znanstveni članek
Organizacija:
FFA - Fakulteta za farmacijo
Status publikacije:
Objavljeno
Različica publikacije:
Objavljena publikacija
Leto izida:
2020
Št. strani:
10 str.
Številčenje:
Vol. 25, iss. 15, art. 3381
PID:
20.500.12556/RUL-133856
UDK:
577.121:615
ISSN pri članku:
1420-3049
DOI:
10.3390/molecules25153381
COBISS.SI-ID:
24851459
Datum objave v RUL:
17.12.2021
Število ogledov:
834
Število prenosov:
170
Metapodatki:
Citiraj gradivo
Navadno besedilo
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Kopiraj citat
Objavi na:
Gradivo je del revije
Naslov:
Molecules
Skrajšan naslov:
Molecules
Založnik:
MDPI
ISSN:
1420-3049
COBISS.SI-ID:
18462981
Licence
Licenca:
CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:
http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:
To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
Začetek licenciranja:
01.08.2020
Sekundarni jezik
Jezik:
Slovenski jezik
Ključne besede:
terapevtska uporaba
,
metaboliti
Projekti
Financer:
EC - European Commission
Program financ.:
H2020
Številka projekta:
765581
Naslov:
Multidisciplinary European Joint Doctorate in the Design and Development of Glyco Drugs
Akronim:
PhD4GlycoDrug
Financer:
Drugi - Drug financer ali več financerjev
Program financ.:
COST actions
Številka projekta:
CA18103
Akronim:
Innogly
Financer:
Drugi - Drug financer ali več financerjev
Program financ.:
COST actions
Številka projekta:
CA18132
Akronim:
GLYCONanoPROBES
Podobna dela
Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:
Nazaj